Acquired HER2 mutations in ER

Antineoplastic Agents, Hormonal / pharmacology Aromatase Inhibitors / pharmacology Breast Neoplasms / drug therapy Cell Line Cell Line, Tumor Cyclin-Dependent Kinase 4 / genetics Cyclin-Dependent Kinase 6 / genetics Drug Resistance, Neoplasm / drug effects Female Fulvestrant / pharmacology HEK293 Cells Humans MCF-7 Cells Mutation / drug effects Piperazines / pharmacology Pyridines / pharmacology Receptor, ErbB-2 / genetics Receptors, Estrogen / genetics Tamoxifen / pharmacology

Journal

Nature genetics
ISSN: 1546-1718
Titre abrégé: Nat Genet
Pays: United States
ID NLM: 9216904

Informations de publication

Date de publication:
02 2019
Historique:
received: 30 10 2017
accepted: 23 10 2018
pubmed: 12 12 2018
medline: 25 4 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

Seventy percent of breast cancers express the estrogen receptor (ER), and agents that target the ER are the mainstay of treatment. However, virtually all people with ER

Identifiants

DOI: 10.1038/s41588-018-0287-5 PMID: 30531871
pubmed: 30531871
doi: 10.1038/s41588-018-0287-5
pii: 10.1038/s41588-018-0287-5
doi:

Substances chimiques

Antineoplastic Agents, Hormonal 0
Aromatase Inhibitors 0
Piperazines 0
Pyridines 0
Receptors, Estrogen 0
Tamoxifen 094ZI81Y45
Fulvestrant 22X328QOC4
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1
Cyclin-Dependent Kinase 4 EC 2.7.11.22
Cyclin-Dependent Kinase 6 EC 2.7.11.22
palbociclib G9ZF61LE7G

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

207-216

Subventions

Organisme : NIH HHS
ID : P50CA168504
Pays : United States

Auteurs

Utthara Nayar (U)

Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Ofir Cohen (O)

Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Christian Kapstad (C)

Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Michael S Cuoco (MS)

Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Adrienne G Waks (AG)

Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
ORCID: 0000-0001-5649-7229

Seth A Wander (SA)

Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Corrie Painter (C)

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Samuel Freeman (S)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Nicole S Persky (NS)

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Lori Marini (L)

Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Karla Helvie (K)

Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Nelly Oliver (N)

Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Orit Rozenblatt-Rosen (O)

Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Cynthia X Ma (CX)

Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.

Aviv Regev (A)

Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Howard Hughes Medical Institute and Koch Institute of Integrative Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.

Eric P Winer (EP)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Nancy U Lin (NU)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Nikhil Wagle (N)

Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA. nikhil_wagle@dfci.harvard.edu.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. nikhil_wagle@dfci.harvard.edu.
Harvard Medical School, Boston, MA, USA. nikhil_wagle@dfci.harvard.edu.
Broad Institute of MIT and Harvard, Cambridge, MA, USA. nikhil_wagle@dfci.harvard.edu.
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. nikhil_wagle@dfci.harvard.edu.
ORCID: 0000-0003-3332-9438

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques hormonaux › Acquired HER2 mutations in ER
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Antihormones › Inhibiteurs de la synthèse des stéroïdes › Inhibiteurs de l'aromatase › Acquired HER2 mutations in ER
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Acquired HER2 mutations in ER
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Acquired HER2 mutations in ER
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Acquired HER2 mutations in ER
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Proline-directed protein kinases › Kinases cyclines-dépendantes › Kinase-4 cycline-dépendante › Acquired HER2 mutations in ER
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Proline-directed protein kinases › Kinases cyclines-dépendantes › Kinase-6 cycline-dépendante › Acquired HER2 mutations in ER
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Acquired HER2 mutations in ER
questionsmedicales.fr › Hormones gonadiques › Hormones sexuelles stéroïdiennes › Congénères de l'oestradiol › Oestradiol › Fulvestrant › Acquired HER2 mutations in ER
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › Acquired HER2 mutations in ER
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Acquired HER2 mutations in ER
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Cellules MCF-7 › Acquired HER2 mutations in ER
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Acquired HER2 mutations in ER
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipérazines › Acquired HER2 mutations in ER
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Acquired HER2 mutations in ER
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Récepteur ErbB-2 › Acquired HER2 mutations in ER
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Récepteurs aux stéroïdes › Récepteurs des oestrogènes › Acquired HER2 mutations in ER
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Composés benzylidéniques › Stilbènes › Tamoxifène › Acquired HER2 mutations in ER